Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the groupe d'etude des lymphomes de i'adulte (GELA) trials

Blood

Volumn 111, Issue 9, 2008, Pages 4463-4470

  Mourad, Nathalie ^a,b,c   Mounier, Nicolas ^d   Brière, Josette ^a,b   Raffoux, Emmanuel ^c   Delmer, Alain ^e   Feller, Alfred ^f   Meijer, Chris J L M ^g   Emile, Jean François ^h   Bouabdallah, Réda ⁱ   Bosly, André ^j   Diebold, Jacques ^k   Haioun, Corinne ^l   Coiffier, Bertrand ^m   Gisselbrecht, Christian ^a,b,c   Gaulard, Philippe ^a,l,n  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h HÔPITAL AMBROISE PARÉ   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^k HÔTEL DIEU   (France)

^l HENRI MONDOR HOSPITAL   (France)

^m Service d'Hématologie   (France)

ⁿ FACULTÉ DE MÉDECINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; VINCRISTINE; VINDESINE; CXCL13 PROTEIN, HUMAN; MEMBRANE METALLOENDOPEPTIDASE;

ADULT; ADVANCED CANCER; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL HYPERPLASIA; CELL SIZE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MEGADOSE; EPITHELIOID CELL; FEMALE; FEVER; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MEDIASTINUM LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMMUNOBLASTIC LYMPHADENOPATHY; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOKINE CXCL13; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; MIDDLE AGED; NEPRILYSIN; PREDNISONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 47149105650     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-105759     Document Type: Article

References (58)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: Pathology and genetics, tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
2. Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood. 1992; 79:1789-1795.
3. Feller AC, Diebold J. Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas. Berlin Heidelberg, Germany: Springer-Verlag; 2004.
4. Abruzzo LV, Schmidt K, Weiss LM, et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood. 1993;82:241-246.
5. Matsue K, Itoh M, Tsukuda K, Kokubo T, Hirose Y. Development of Epstein-Barr virus-associated B cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia. Int J Hematol. 1998;67:319-329.
6. Lome-Maldonado C. Canioni D, Hermine O, et al. Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection: a different subtype of AILD-TL? Leukemia. 2002;16:2134-2141.
7. Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol. 2007;31:1077-1088.
8. Krenacs L, Schaerli P. Kis G, Bagdi E. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood. 2006;108:1110-1111.
9. de Leval L, Rickman DS, Thielen C. et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T cells (TFH). Blood. 2007;109:4952-4963.
10. Vinuesa CG. Tangye SG, Moser B. Mackay CR. Follicular B helper T cells in antibody response and autoimmunity. Nat Rev Immunol. 2005;5:853-865.
11. Attygalle A, Al Jehani R. Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627-633.
12. Dogan A. Attygalle AD. Kyriakou C. Angioimunoblastic T-cell lymphoma. Br J Haematol. 2003; 121:681-691.
13. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in Angioimmunoblastic T cell-lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006; 30:490-494.
14. Grogg KL Attygalle AD. Macon WR. Remstein ED, Kurtin PJ, Dogan A. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood. 2005;106:1501-1502.
15. Aclinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
16. Pangalis GA, Moran EM. Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angioimmunoblastic lymphadenopathy: long term follow up study. Cancer. 1983;52:318-321.
17. Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ. Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer. 1987; 59:208-212.
18. Aozasa K, Ohsawa M, Fujita MQ, et al. Angioimmunoblastic lymphadenopathy: review of 44 patients with emphasis on prognostic behavior. Cancer. 1989;63:1625-1629.
19. Siegert W, Nerl C, Ag the A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation: The Kiel Lymphoma Study Group. Ann Oncol. 1995;6:659-664.
20. Chfang HJ, Su IJ, Chen CH, et al. Angioimmunoblastic lymphadenopathy with dysproteinemia: lack of prognostic value of clear cell morphology. Oncology. 1997;54:193-198.
21. Pautier P, Devidas A, Delmer A, et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma. 1999; 32:545-552.
22. Lee SS, Rudiger T, Odenwald Roth S, Starostik P, Muller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer. 2003;103:12-20.
23. Lachenal F, Berger F, Ghesquieres H, et al. Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine. 2007;86:282-292.
24. Gisselbrecht C, Gaulard P. Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas: Groupe d'Etude des Lymphomes de I'Adulte (GELA). Blood. 1998:92:76-82.
25. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage: The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-2135.
26. Stansfeld AG, Diebold J, Noel H. etal. Updated Kiel classification for lymphomas. Lancet. 1998;1:292-293.
27. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
28. Tilly H, Mounier N, Lederlin P, et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study: Groupe d'Etude des Lymphomes de I'Adulte. J Clin Oncol. 2000; 18:1309-1315.
29. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol: a Groupe d'Etude des Lymphomes de I'Adulte study. J Clin Oncol. 2000;18:3025-3030.
30. Bosly A, Lepage E, Coiffier B, et al. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. Hematol J. 2001;2:279-285.
31. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197-1205.
32. Gisselbrecht C, Lepage E. Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472-2479.
33. Bonnet C, Fillet G, Mounier N. et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de I'Adulte. J Clin Oncol. 2007;25:787-792.
34. Tilly H, Lepage E, Coiffier B. et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003; 102:4284-4289.
35. Bastion Y, Blay JY, Divine M. et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival: a Groupe d'Etude des Lymphomes de I'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945-2953.
36. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7:1018-1026.
37. Cheson BD, Horning SJ, Coiffier B. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
38. Kaplan EL, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
39. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
40. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474-2479.
41. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472-2479.
42. Frizzera G, Moran E, Rappaport H. Angioimmunoblastic lymphadenopathy with dysproteinemia. Am J Med. 1975;1:1070-1073.
43. Lukes R, Tindle B. Immunoblastic lymphadenopathy: a hyperimmune entity resembling Hodgkin's disease. N Eng J Med. 1975;292:1-8.
44. Tobinai K, Minato K, Ohtsu T, et al. Clinicopathologic, immunophenotypic and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. Blood. 1998;72:1000-1006.
45. Mounier N, Gisselbrecht C, Briere J, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de I'Adulte (GELA). Ann Oncol. 2004;15:1790-1797.
46. Schetelig J, Fetscher S, Reichle A, et al. Longterm disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica. 2003;88:1272-1278.
47. Kyriakou C, Canals C, Goldstone A, et al. Highdose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome: Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. Prepublished on December 10, 2007, as doi:10.1200/JCO-2008-12-6219.
48. Ree HJ, Kadin ME. Kikuchi M, et al. Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers. Am J Surg Pathol. 199822:643-655.
49. Nathwani BN, Rappaport H, Moran EM, Pangalis GA, Kim H. Malignant lymphoma arising in angioimmunoblastic lymphadenopathy. Cancer. 1978; 41:578-606.
50. Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. Blood. 2004;104:1952-1960.
51. Chtanova T, Tangye SG, Newton R, et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol. 2004;173:68-78.
52. Ansel KM, Ngo VN, Hyman PL, at al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000:406:309-314.
53. Grogg KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol. 2006;19:1101-1107.
54. Advani R, Warnke R, Sikic Bl, Horning S. Treatment of angioimmunoblastic T-cell lymphoma, with cyclosporine. Ann Oncol. 1997;8:601-603.
55. Quintini G, lannitto E, Barbera V, et al. Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma. Hematol J. 2001; 2:393-395.
56. Siegert W, Nerl C, Meuthen I, et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy: results in 12 patients. Leukemia. 1991;5:892-895.
57. Ong ST, Koeppen H, Larson RA, Olopade Ol. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood. 1996;88:2354-2355.
58. Mourad N, Mounier N, Briere J, et al. Angioimmunoblastic T-cell lymphoma: a clinicopathologic study of 158 patients treated in GELA trials. Blood. 2006;108:121 a. Abstract 397.